Monday, October 5, 2026

Technology

79 articles

AI Infrastructure Stocks: Separating Growth from Hype

AI Infrastructure Stocks: Separating Growth from Hype

Investors are eyeing significant growth in AI infrastructure companies amid soaring demand for AI compute, but concerns over speculative hype and financial strain persist.

ViaNews Editorial Team (Markets)•
Dow Jones Hits 50,000: Bull Market Peak or Overvaluation Risk?

Dow Jones Hits 50,000: Bull Market Peak or Overvaluation Risk?

The Dow Jones reaching significant round numbers has sparked both excitement and concern among investors. While some see it as a sign of increased confidence and potential for new records, others worry about overvaluation and inflationary pressures.

ViaNews Editorial Team (Markets)•
Microsoft Downgraded as AI Race Heats Up

Microsoft Downgraded as AI Race Heats Up

Stifel cuts Microsoft to 'Hold', citing the need for a break, while analysts debate the long-term impact of increased AI investments on tech giants.

ViaNews Editorial Team (Markets)•
Intel vs Nvidia: Can the Chip Giant Keep Pace in 2025?

Intel vs Nvidia: Can the Chip Giant Keep Pace in 2025?

Intel's stock rebounded and outperformed Nvidia's in 2025, but analysts remain divided on its long-term prospects. While some see potential in Intel's collaboration with Nvidia, others warn of overvaluation and dependency risks.

ViaNews Editorial Team (Markets)•
Alphabet's $180B AI Bet: Bold Strategy or Financial Risk?

Alphabet's $180B AI Bet: Bold Strategy or Financial Risk?

Alphabet's shares dropped in pre-market trading after the company announced higher-than-expected spending plans for the upcoming year. Analysts are divided on whether this increased investment will drive innovation or lead to financial strain.

ViaNews Editorial Team (Markets)•
Quantum Computing Stocks: Investment Opportunity or Market Hype?

Quantum Computing Stocks: Investment Opportunity or Market Hype?

Quantum computing stocks are gaining significant attention for their potential to revolutionize technology. However, concerns over high R&D costs and unrealistic expectations create a tense balance between promise and risk.

ViaNews Editorial Team (Markets)•
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,340 source documents archived
Query this data → isubstrate.com